Tuesday January 17, 2017 0 comments
BOULDER -- InDevR, a Boulder-based progressive analytical technology and life science instrumentation company, today announced it has entered into an agreement to license monoclonal antibodies from the US Food and Drug Administration (FDA).
The agreement enables InDevR to consistently manufacture and control the supply of antibodies for use in its potency assays, the company said.
It also offers increased reliability and control if vaccine production scaling is needed in the event of an influenza pandemic.
As a maker of the VaxArray Vaccine Potency platform, InDevR said it is focused on providing vaccine manufacturers with streamlined and cost-efficient tools to modernize vaccine production.
The commercially available VaxArray Influenza Seasonal Hemagglutinin Kit for seasonal influenza vaccine potency is used by manufacturers and developers for quantification of hemagglutinin within influenza vaccines.
InDevR also has a strong product development pipeline that includes VaxArray reagent kits for pandemic HA and flu neuraminidase.
“This agreement is an important step to ensure that our product continues to meet the needs of the influenza vaccine industry,” said Dr. Kathy Rowlen, InDevR CEO.
“The flu virus is a moving target and scientists at the FDA are on the frontlines of understanding antigenic changes in the virus. We are fortunate to license the antibodies developed by those scientists in response to antigenic changes.”